Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F23%3A10470620" target="_blank" >RIV/00179906:_____/23:10470620 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/23:10470620

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=SYXmfLqLR9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=SYXmfLqLR9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12325-023-02644-5" target="_blank" >10.1007/s12325-023-02644-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Popis výsledku v původním jazyce

Introduction: Insights into real-world treatment of atopic dermatis (AD) are relevant to clinical decision making. The aim of this analysis was to charakterize patients who receive dupilumab for AD in real-world setting. Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receiveč dupilumab according to ciuntry-specific prescribing information. We report baseline characteristics, comorbidites and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean standard deviation) percent body surface area affected (44.8, 24.42, Eczema Area and Severity Index total score (24.8, 12.95, SCORing Atopic Dermatitis total score (60.5 - 19.34, Patient-Oriented Eczema Measure total score (19.7 - 6.37) and Dermatology Life Quality Index total score (13.7 [7.02]. Overall, 741 (77 %) patients reported 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7 %], asthma (323 [33.9 %], food allergy (294 [30.9 %] or anothert allergy (274 [28.8 %]. In the previous 12 months, 310 (32.6 %) patients had received systemic non-steroidal immunosuppressant and 169 (17.8 %) systemic corticosteroids; 141 (14.8 %) had received topical calcineurin inhibitors and 32 (3.4 %) ultraviolet therapy. Most (713 [74.9 %] patients started dupilumab because of prior treatment failure. Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic AD treatments. Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417.

Název v anglickém jazyce

Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Popis výsledku anglicky

Introduction: Insights into real-world treatment of atopic dermatis (AD) are relevant to clinical decision making. The aim of this analysis was to charakterize patients who receive dupilumab for AD in real-world setting. Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receiveč dupilumab according to ciuntry-specific prescribing information. We report baseline characteristics, comorbidites and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean standard deviation) percent body surface area affected (44.8, 24.42, Eczema Area and Severity Index total score (24.8, 12.95, SCORing Atopic Dermatitis total score (60.5 - 19.34, Patient-Oriented Eczema Measure total score (19.7 - 6.37) and Dermatology Life Quality Index total score (13.7 [7.02]. Overall, 741 (77 %) patients reported 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7 %], asthma (323 [33.9 %], food allergy (294 [30.9 %] or anothert allergy (274 [28.8 %]. In the previous 12 months, 310 (32.6 %) patients had received systemic non-steroidal immunosuppressant and 169 (17.8 %) systemic corticosteroids; 141 (14.8 %) had received topical calcineurin inhibitors and 32 (3.4 %) ultraviolet therapy. Most (713 [74.9 %] patients started dupilumab because of prior treatment failure. Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic AD treatments. Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Advances in Therapy

ISSN

0741-238X

e-ISSN

1865-8652

Svazek periodika

40

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

5366-5382

Kód UT WoS článku

001082051600005

EID výsledku v databázi Scopus

2-s2.0-85173774720